Stay up-to-date on our latest developments
OXURION NV to Present at Wet AMD and DME Drug Development Summit
Leuven, BE, Boston, MA, US – April 13th, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, today announces that Grace Chang, M.D., Ph.D., Chief Medical Officer (CMO) of Oxurion, will be presenting at the Wet AMD and DME Drug Development Summit, taking place from April 13 to 15, 2021.
Dr. Chang will be joining the Summit as a presenter and a panelist:
- Presentation on New Therapeutics Target RGD Integrins and The Plasma Kallikrein System: Overview of First Clinical Findings
Date & Time: April 15, 2021 at 9:55 am EDT
- Participation in Q&A session entitled Targeting New Therapeutic Pathways & Looking Beyond Anti-VEGF
Date & Time: April 15, 2021 at 10:35 am EDT
- Participation in Panel Discussion on the Topic Searching for Novel Therapeutic Targets – Addressing Developmental Challenges for New Drug Candidates in Wet AMD & DME
Date & Time: April 15, 2021 at 11:10 am EDT
For more information and registration details: https://wet-amd-drugdevelopment.com
Under the leadership of Dr. Chang, Oxurion is advancing a pipeline of innovative clinical drug candidates with distinct and complementary modes of action, for treatment of retinal vascular disorders, including DME but also wet AMD.
THR-149 is a potential first in class plasma kallikrein inhibitor with the possibility to become the treatment of choice for the 40% DME patients who respond sub-optimally to anti-VEGF therapy. Oxurion is currently recruiting patients in a Phase 2 and is on track to readout Part A data later this year.
THR-687 is a potential best in class small molecule pan-RGD integrin antagonist initially being developed to treat DME with the possibility to become the standard of care for most DME patients. The Company is currently preparing an IND to start a Phase 2 study evaluating THR-687 as a new therapy for most DME patients. This Phase 2 is expected to start in mid-year.
Beyond DME, THR-687 also has development possibilities in additional retinal vascular disorders including for wet age-related macular degeneration (Wet AMD) and retinal vein occlusion (RVO), thereby potentially allowing the Company to tap into a broader therapeutic market with a current combined estimated annual value of $12 billion.